CN100446800C - Chinese traditional medicine composition - Google Patents
Chinese traditional medicine composition Download PDFInfo
- Publication number
- CN100446800C CN100446800C CNB2006100653126A CN200610065312A CN100446800C CN 100446800 C CN100446800 C CN 100446800C CN B2006100653126 A CNB2006100653126 A CN B2006100653126A CN 200610065312 A CN200610065312 A CN 200610065312A CN 100446800 C CN100446800 C CN 100446800C
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- crude drug
- medicine
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a Chinese medicine composition, drug including the said composition, preparation method and application thereof. The said composition is composed of 15-35 portions of wolfberry, 10-25 portions of dendrobium stem, 10-25 portions of radix salviae miltiorrhizae, 5-20 portions of tree peony bark, 5-20 portions of figwort, 5-20 portions of chrysanthemum and 5-20 portions of radix notoginseng by weight. The souce of the said compositin may be readitional chinese medicinal materials and the extract amount to the raw medicine amount of the said readitional chinese medicinal materials. The composition can be used for treatment of severe complications of diabetes such as diabetic retinopathy.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, specifically, it is the Chinese medicine composition that can blood sugar lowering makes eye bright, especially can be used for treating the severe complication of diabetes, diabetic retinopathy for example, the component of said composition can be directly to be ground into Chinese crude drug that powder is used as medicine or the Chinese medicine extract that obtains through extraction.
Background technology
Diabetic retinopathy is one of severe complication of diabetes, its pathological changes shows as that microangioma forms, the change of hemorrhage, blood vessel such as edema is oozed out, and causes retinal edema, cystoid macular edema, retinal hemorrhage, and blood capillary is inaccessible and new vessels forms.There are data to show, the diabetic duration of population of China is more than 8 years, the diabetic renal papillary necrosis person is taken place to be accounted for more than 50%, prolongation along with the course of disease, incidence of diabetic retinopathy increases thereupon, the early stage normal no conscious sympton of eye, along with pathological changes increase the weight of visual deterioration can be arranged, shadow and metamorphopsia etc. are arranged at the moment, and severe patient can cause visual loss.Diabetic renal papillary necrosis does not still have correspondingly name of disease in Chinese medicine, according to the clinical manifestation of the different phase of the course of disease, can belong to the category of Chinese medicine diseases such as " blurring of vission ".
Because diabetic renal papillary necrosis is that diabetes cause, so its etiology and pathogenesis has inseparable relation with diabetes, and the etiology and pathogenesis of diabetes is more than natural endowment deficiency, the plain body deficiency of YIN; Or because of intemperance of taking food; Or because of feelings will unsuccessful; Or because of due to labor desires excessively.The clinical manifestation of diabetic renal papillary necrosis has diseases such as the deficiency of YIN is scorching, deficiency of both QI and YIN, the hepatic and renal YIN deficiency, deficiency-weakness of spleen-QI, blood-stasis internal-depression.
The medicine that is used for the treatment of diseases such as diabetic renal papillary necrosis now is a lot, as: Radix Rehmanniae Pilulae for Improving Eyesight etc., in the clinical practice, reasons such as these medicines are mostly coarse because of preparation, quality is wayward, stability of drug products is relatively poor cause it not dominate the market for a long time, it is blank to this shows that Chinese patent medicine is still comparatively speaking in the treatment market of diabetic renal papillary necrosis, thus market in urgent need develop a kind of determined curative effect and significantly, the Chinese medicine medicine that becomes of sophisticated technologies, treatment of diabetic retinopathy that drug quality is stable.
Summary of the invention
The inventor comes from theory of Chinese medical science, sums up experience in many ways, and ancient prescription and experience reef knot are closed, and carries through the clinical practice empirical to form.The present invention is a Chinese medicine composition, is preferably made through extracting by seven flavor Chinese medicines, can improve diseases such as the deficiency of YIN is scorching, deficiency of both QI and YIN, the hepatic and renal YIN deficiency, deficiency-weakness of spleen-QI, blood-stasis internal-depression greatly, and the determined curative effect of blood circulation-activating eyesight-improving, and is safe and effective.
The object of the present invention is to provide a kind of Chinese medicine composition and comprise the medicine of said composition, said composition and medicine have the effect that blood sugar lowering makes eye bright.
The present invention also aims to provide manufacturing method for above mentioned medicine,, can obtain being used for the treatment of evident in efficacy, the sophisticated technologies of diabetic renal papillary necrosis, stay-in-grade pharmaceutical composition by this method.
Of the present inventionly also provide the application of above-mentioned Chinese medicine composition in the medicine that preparation treatment treatment of diabetic retinopathy becomes.
In order to achieve the above object, the invention provides a kind of Chinese medicine composition, crude drug by following weight is formed: Fructus Lycii 15-35 part, Herba Dendrobii 10-25 part, Radix Salviae Miltiorrhizae 10-25 part, Cortex Moutan 5-20 part, Radix Scrophulariae 5-20 part, Flos Chrysanthemi 5-20 part and Radix Notoginseng 5-20 part, the source of described crude drug can be Chinese crude drug or the Chinese medicine extract that is equivalent to above-mentioned Chinese crude drug crude drug amount.
Above-mentioned composition of the present invention is primarily aimed at diseases such as diabetic renal papillary necrosis and sets up, and it is a Chinese medicine compound, pays attention to blood circulation promoting and blood stasis dispelling, nourishing the liver and kidney, blood circulation-activating eyesight-improving, and the medicine source of crude drug is extensive, has no side effect.
Composition prescription of the present invention is reasonable, according to the side of traditional medicine separating, is monarch drug with the Fructus Lycii in the side, is used for the treatment of and quenches one's thirst, and the blurred vision that causes quenching one's thirst is particularly suitable; Herba Dendrobii, Radix Salviae Miltiorrhizae are ministerial drug; Cortex Moutan, Radix Scrophulariae, Flos Chrysanthemi and Radix Notoginseng are adjuvant drug; All medicines share, and gather the effect of nourishing the liver and kidney, blood circulation-activating eyesight-improving altogether.
The preferred Flos Chrysanthemi of the Flos Chrysanthemi that adopts in the compositions of the present invention.
In the compositions of the present invention, can select the whole starch of flavour of a drug, form that also can extract is used as medicine, as long as comprised the above-mentioned raw materials medicine, said composition can reach the drug effect that treatment of diabetic retinopathy becomes.In a preferred embodiment of the invention, Fructus Lycii, Herba Dendrobii, Radix Salviae Miltiorrhizae, Radix Scrophulariae and (Hangzhoupro) Flos Chrysanthemi are used as medicine with the form of water extract; Radix Notoginseng and Cortex Moutan are used as medicine with the form of alcohol extract, and water extract and alcohol extract are merged into medicinal liquid, preferably are condensed into extractum, get final product.
In a preferred embodiment of the invention, the crude drug of aforementioned pharmaceutical compositions is formed proportioning (weight) preferably:
Fructus Lycii 20-30 part, Herba Dendrobii 15-20 part, Radix Salviae Miltiorrhizae 15-20 part, Cortex Moutan 10-15 part, Radix Scrophulariae 10-15 part, Flos Chrysanthemi 10-15 part and Radix Notoginseng 10-15 part, more preferably 25.2 parts of Fructus Lycii, 16.8 parts of Herba Dendrobiis, 16.8 parts of Radix Salviae Miltiorrhizaes, 12.6 parts of Cortex Moutans, 12.6 parts of Radix Scrophulariaes, 12.6 parts of Flos Chrysanthemis and Radix Notoginseng are 12.6 parts.
The present invention also provides a kind of medicine that can blood sugar lowering makes eye bright, it comprises above-mentioned Chinese medicine composition and pharmacy acceptable auxiliary, difference according to pharmaceutical dosage form, selected adjuvant is also different, in this medicine, it can be any dosage form, be preferably peroral dosage form, it is that on the pharmacy meaning all can supply oral dosage form, for example honeyed pill, water-honeyed pill, the watered pill, granule, capsule, tablet, oral liquid or syrup, more preferably granule, capsule and oral liquid, in an embodiment of the present invention, capsule most preferably.Pharmacological effect experimental results show that, the curative effect of medicine of the present invention obviously is better than the existing Chinese patent medicine that can blood sugar lowering makes eye bright, and (for example: Radix Rehmanniae Pilulae for Improving Eyesight etc.), by comparison, the present composition has farthest reduced dosage, made things convenient for and taken, and improved drug effect.
The present invention also provides manufacturing method for above mentioned medicine, comprising:
(1) Radix Notoginseng and Cortex Moutan are got alcohol extract with alcohol extraction;
(2) Fructus Lycii, Herba Dendrobii, Radix Salviae Miltiorrhizae, Radix Scrophulariae and chrysanthemum with water are extracted, and with the alcohol precipitation, get supernatant and get water extract;
(3) alcohol extract and water extract are merged, get final product.
Can also continue to be concentrated into relative density 1.00-1.25 (about 55 degrees centigrade) and make extractum.
In order to obtain the pharmaceutical composition that active component is more stable, active constituent content is higher, available ethanol is as extracting solvent in the above-mentioned steps (1), and the ethanol of preferred 70-80% can extract with A Kuanyi mixed extraction respectively; Be used for precipitating the pure preferred alcohol of remove impurity in the step (2); Behind the preferred extracting in water of step (2) (extracting respectively or mixed extraction), filter, filtrate adds ethanol precipitation, adds amount of alcohol to solution and contains ethanol and reach about 60%, and precipitation is got supernatant.
The technology that the present composition is prepared into various peroral dosage forms is as follows:
The granule dosage form: above-mentioned extractum is added dextrin or other binding agent, and fully mixing is put 60-80 ℃ of drying, pulverizes; With the abundant mixing of correctives (as steviosin), granulate again, drying, promptly.
Tablet: above-mentioned extractum is added dextrin or other binding agent, and fully mixing is put 60-80 ℃ of drying and crushing; Also can add correctives as required, add suitable amount of adhesive (for example starch) mixing, granulation, drying add moderate lubrication agent (for example magnesium stearate), disintegrating agent (carboxymethyl starch sodium) mixing again, and tabletting also can carry out coating, promptly as required.
Capsule: above-mentioned extractum is added dextrin or other binding agent, abundant mixing, drying is pulverized; With correctives (as steviosin), an amount of filler (as starch) mixing, drying incapsulates, promptly again.
According to this area routine techniques, compositions of the present invention also can be made into honeyed pill, water-honeyed pill, the watered pill, wax pill, concentrated pill, and its processing step is routine operation, and visual medical material situation difference takes the circumstances into consideration to change process conditions, and it is conventionally known to one of skill in the art.
At the difference of needed product, the preparation process of medicine of the present invention also can be different, but are the common practise preparation process, describe no longer one by one.
In above-mentioned preferred embodiment, the design of the concrete parameter of preparation were established is according to the character of different Chinese crude drugs and pharmacological action difference, definite with screening by analysis optimization technology experiment showed, that through pharmacology pharmacodynamic it is rational selection process scheme.The technical conditions of extracting (optimum technology parameter of extraction) are to be index with the paste-forming rate, adopt three factors, three water-glasses to carry out that orthogonal test determines.
The Chinese crude drug that is adopted in the compositions of the present invention is the medical material that version pharmacopeia in 2000 is recorded, and through identifying, every index all meets the pharmacopeia regulation.
The qualitative evaluation of compositions of the present invention and medicine: the experiment of pressing an appendix VIB of Chinese Pharmacopoeia version in 2000
Method, the present composition and medicine be formulated in control medicinal material chromatograph relevant position on show same blob, prove that the present composition contains Fructus Lycii, Herba Dendrobii, Radix Salviae Miltiorrhizae, Cortex Moutan, Radix Scrophulariae, Flos Chrysanthemi and Radix Notoginseng.
The inspection of arsenic salt and heavy metal in the present composition and the medicine: press the regulation under appendix IXE of Chinese Pharmacopoeia version in 2000, the IXF item, the arsenic salt and the heavy metal of sample are checked that the result is in prescribed limit.
The health examination of the present composition and medicine: meet hygiology standard of pharmacopeia.
The toxicological study of the present composition and medicine: mice is 95.2g crude drug/kg to the maximum dosage-feeding of the present composition and medicine, is equivalent to 435.9 times of clinical consumption 0.2184g crude drug/Kg.
The invention provides the application of above-mentioned composition in the medicine that the preparation treatment of diabetic retinopathy becomes.
The pharmacology pharmacodynamic experimental study
Experimental drug: the capsule medicine of the embodiment of the invention 1 (hereinafter referred to as the blood sugar lowering capsules for improving vision);
Contrast medicine: Mingmu-Dihuang nine (manufacturer is Boran Pharmaceutical Co., Ltd., Beijing); YIKAI (the kallidinogenase enteric coatel tablets, the microcirculation improvement effect is mainly used in diseases with microcirculatory disturbance, the nephropathy that causes as diabetes, peripheral neuropathy, retinopathy etc., Qianhong Biochemical Pharmaceutical Co., Ltd., Changzhou produces).
Laboratory animal: the C57BL/B male mice, buy by Beijing Vital River Experimental Animals Technology Co., Ltd., be the SPF/VAF level.
Reagent: (streptozotocin STZ) buys reagent by U.S. Sigma company to chain rouge assistant rhzomorph; The blood glucose meter reagent paper.
Main test blood sugar lowering capsules for improving vision of the present invention is to the retinopathy inhibitory action of STZ diabetic mice.
Experimental technique:
The foundation of STZ diabetes model: the mice adaptability was raised 3 days, survey fasting glucose and all be lower than 7mmol/L, be divided into normal control group, STZ model control group, Radix Rehmanniae Pilulae for Improving Eyesight matched group, YIKAI matched group, the large, medium and small dosage group of blood sugar lowering capsules for improving vision at random, 10 every group.Mice 15 hours on an empty stomach, STZ (STZ is dissolved in the citrate buffer of 0.1M, PH4.4, filtering with microporous membrane degerming, the fresh use) dosage of disposable celiac injection 2% is the 175mg/kg body weight.The citrate buffer solution of normal control group mouse peritoneal injection equal dose.
Dosage and method:
Mingmu-Dihuang nine: the mice dosage is 3.6g/kg/ day, once-a-day, and successive administration 80 days.
YIKAI: the mice dosage was 108 μ g/kg/ days, 1 time/day, and successive administration 80 days.
The large, medium and small dosage group of blood sugar lowering capsules for improving vision gives 3.93,1.96 respectively, 0.98g crude drug/kg, once-a-day, and successive administration 80 days.
Normal control group and STZ model control group give pure water every day.
The mensuration of blood glucose and body weight:
Bringing out the back the 3rd, 7,30 and 60 day, get mouse tail blood and survey fasting glucose with blood glucose meter, weigh in.
The eyeball check pathological section:
Bringing out the back the 80th day, get respectively and respectively organize eyeball of mouse, spend the night with 10% formaldehyde fixed, dehydration, the utmost point is cut eyeball open to optic nerve, wax embedding before the sagittal plane cornea, carry out 4 μ m section from the utmost point before the sagittal plane cornea to optic nerve with the pathological section machine, carry out conventional H E dyeing.Every mice is got 3 sections at random, and retinal vessel counting and photograph are carried out in every section.
Statistical analysis: the result tests with SPSS6.0 software.
The result:
1. general situation and body weight: control group mice amount of drinking water every day is few, and the urine amount is few, and fur is smooth, submissive, and body weight is with increasing and steady-state growth age in week; STZ model control group mice amount of drinking water every day and urine amount are obviously more than the normal control group, and body weight obviously alleviates.Radix Rehmanniae Pilulae for Improving Eyesight, YIKAI and blood sugar lowering capsules for improving vision treatment group mice amount of drinking water every day and urine amount and STZ model bring out group does not have obviously difference, and body weight all significantly alleviates than normal group.But the weight ratio Radix Rehmanniae Pilulae for Improving Eyesight matched group of the heavy dose of treatment group of blood sugar lowering capsules for improving vision mice obviously increases.Each is organized the mice body weight and sees Table 1
The influence of table 1. pair STZ diabetic mice body weight
*P＜0.05
*Compare with model control group P＜0.01
2. fasting glucose: inject after STZ3 days, each is organized the mice fasting glucose and all obviously raises, Radix Rehmanniae Pilulae for Improving Eyesight, YIKAI and low dose of blood sugar lowering capsules for improving vision do not have obvious influence to the rising of blood glucose, but heavy dose of and middle dosage blood sugar lowering capsules for improving vision can suppress the rising of blood glucose to a certain extent, and the effect of dosage blood sugar lowering capsules for improving vision is more obvious in heavy dose of blood sugar lowering capsules for improving vision ratio.After injected in mice STZ3 days, middle dosage blood sugar lowering capsules for improving vision can not suppress the rising of blood glucose, but after 7 days, the blood glucose of middle dosage blood sugar lowering capsules for improving vision treatment group mice is starkly lower than simple STZ and brings out group, P＜0.05; And heavy dose of blood sugar lowering capsules for improving vision treatment group mice is behind STZ3 days P＜0.05 and 7 day P＜0.01 of injection, and its fasting glucose all is starkly lower than model control group.Though the blood sugar lowering capsules for improving vision can not make blood sugar recovery to normal level, it is sure to the inhibitory action of blood sugar increasing.Each is organized mice fasting glucose concentration and sees Table 2.
The influence of table 2. pair STZ diabetic mice fasting glucose
*P＜0.05
*Compare with model control group P＜0.01
3. retinal vessel inspection and counting: blood capillary is few in the normal mouse retina.Behind the injected in mice STZ 80 days, blood capillary showed increased in the retina, P＜0.01; Although Radix Rehmanniae Pilulae for Improving Eyesight and YIKAI are to blood sugar increasing unrestraint effect, but vascular counts that should treatment group mice is starkly lower than the STZ model control group, P＜0.01, the capsule of large, medium and small dosage all can significantly suppress the change of retinal vessel, trunk does not have obviously and attenuates in the retina, blood capillary does not have showed increased, P＜0.01; Its effect obviously is better than Radix Rehmanniae Pilulae for Improving Eyesight and YIKAI.
Each organizes the retinal vessel counting.The results are shown in Table 3.
The influence of table 3. pair STZ diabetic mice vascular counts
*P＜0.05
*Compare with model control group P＜0.01; Compare with Radix Rehmanniae Pilulae for Improving Eyesight,
=P0.01
4. retina pathology is checked: each layer queueing discipline in the normal mouse retina, and the ganglion cell is evenly neat, and blood vessel wall is level and smooth in the nerve fibre layer, and tube chamber is bigger, blood capillary negligible amounts in the retina; After injected in mice STZ80 days, the visible tube wall thickening of trunk in the retina, tube chamber obviously attenuates, and a large amount of new vesselses occur and microangioma occurs, and is prominent to vitreous chamber.The retinal ganglion cellular swelling, arrangement disorder, internal limiting membrane thickens, and inner molecular layer has swelling, and the external plexiform layer blood capillary occurs, and outer nuclear layer changes little.Each treatment group retina pathology changes all less than model group, there is no microangioma and occurs; Heavy dose of blood sugar lowering capsules for improving vision can significantly suppress the amphiblestroid pathological change of mice, the basic queueing discipline of each layer in the retina, and new vessels obviously reduces than model group, and ganglion-cell layer changes not obvious.
This experiment has been carried out laboratory observation with regard to its main pharmacodynamics, utilizes chain clothes assistant rhzomorph (STZ)-diabetic mice model to carry out Drug therapy, and the observation experiment medicine is to the influence of mouse blood sugar and retinal vasculopathy.Experimental result shows: the body weight of bringing out male mice with STZ obviously reduces, fasting glucose obviously raises, vascular counts increases in the retina, retinal ganglion cellular neural fibrous layer thickens, the disorder of ganglion cell's nuclear arrangement: the large, medium and small dosage group of blood sugar lowering capsules for improving vision can significantly be alleviated the STZ diabetic mice and lose weight; The rising that dosage group big or middle can make STZ cause the mice fasting glucose has tangible reduction effect, and large, medium and small dosage group can make the interior vascular counts of retina obviously reduce than the STZ-diabetic mice, and retinal ganglion cellular neural fibrous layer changes not obvious.
Conclusion: medicine of the present invention has inhibitory action to the retinal neovascularization hypertrophy that STZ brings out diabetic mice.
The specific embodiment
For more clear explanation goal of the invention and technical scheme, be described in further detail by following embodiment.
Embodiment 1:
Composition prescription of the present invention: Fructus Lycii 252g, Herba Dendrobii 168g, Radix Salviae Miltiorrhizae 168g, Cortex Moutan 126g, Radix Scrophulariae 126g, Flos Chrysanthemi 126g and Radix Notoginseng 126g.
Preparation method:
Above seven flavor medicine, Radix Notoginseng, Cortex Moutan add 75% alcohol reflux three times, and each 1.5 hours, add 6 times of amounts of ethanol, filter, reclaim ethanol and get medicinal liquid; All the other Fructus Lycii, Herba Dendrobii, Radix Salviae Miltiorrhizae, Radix Scrophulariae and Flos Chrysanthemi decoct with water secondary, each 1.5 hours, add 10 times of amounts of water, collecting decoction filters, and filtrate adds ethanol and reaches 60% to containing the alcohol amount, left standstill 24 hours, filter, recovery ethanol merges with the medicinal liquid that above-mentioned alcohol extraction obtains again, being concentrated into relative density is 1.08-1.10 (55 ℃), drying under reduced pressure becomes dried cream, pulverizes, and promptly obtains compositions of the present invention.
Capsule preparation method thereof:
Above-mentioned compositions that obtains and appropriate amount of starch mixing incapsulate to 400g, get final product.
The clinical recommended dose of this capsule is 1.6g/ time, 3 times/day.
Embodiment 2:
Composition prescription: 15 parts of 20 parts of Fructus Lycii, 15 parts of Herba Dendrobiis, 15 parts of Radix Salviae Miltiorrhizaes, 10 parts of Cortex Moutans, 10 parts of Radix Scrophulariaes, 10 parts of Flos Chrysanthemis and Radix Notoginseng.
Preparation method:
Above seven flavor medicine, Radix Notoginseng, Cortex Moutan add 70% alcohol reflux 2 hours, add 3 times of amounts of ethanol, filter, and reclaim ethanol and get medicinal liquid; All the other Fructus Lycii, Herba Dendrobii, Radix Salviae Miltiorrhizae, Radix Scrophulariae and Flos Chrysanthemi decoct with water 2 hours, add 5 times of amounts of water, collecting decoction, filter, filtrate adds ethanol and reaches 60% to containing the alcohol amount, leaves standstill 24 hours, filters, reclaim ethanol, the medicinal liquid that obtains with above-mentioned alcohol extraction merges again, and being concentrated into relative density is 1.08-1.10 (55 ℃), and drying under reduced pressure becomes dried cream, pulverize, promptly obtain compositions of the present invention.
Method for preparing tablet thereof:
The dried cream of the above-mentioned compositions that obtains is added dextrin, and fully mixing is put 60-80 ℃ of drying and crushing; Add appropriate amount of starch and disintegrating agent carboxymethyl base Starch Sodium, mixing, granulation, drying add moderate lubrication agent magnesium stearate again, mixing, tabletting, promptly.
The also available Flos Chrysanthemi of above-mentioned raw materials medical material Flos Chrysanthemi substitutes, better effects if.
Embodiment 3:
Composition prescription: 10 parts of 30 parts of Fructus Lycii, 20 parts of Herba Dendrobiis, 20 parts of Radix Salviae Miltiorrhizaes, 15 parts of Cortex Moutans, 15 parts of Radix Scrophulariaes, 15 parts of Flos Chrysanthemis and Radix Notoginseng.
Preparation method:
Above seven flavor medicine, Radix Notoginseng, Cortex Moutan add 80% alcohol reflux, add 2 times of amounts of ethanol, filter, and reclaim ethanol and get medicinal liquid; All the other Fructus Lycii, Herba Dendrobii, Radix Salviae Miltiorrhizae, Radix Scrophulariae and Flos Chrysanthemi decoct with water, and add 3 times of amounts of water, collecting decoction, filter, filtrate adds ethanol and reaches 60% to containing the alcohol amount, leaves standstill 24 hours, filters, reclaim ethanol, the medicinal liquid that obtains with above-mentioned alcohol extraction merges again, and being concentrated into relative density is 1.08-1.10 (55 ℃), and drying under reduced pressure becomes dried cream, pulverize, promptly obtain compositions of the present invention.
Process for producing granula:
The above-mentioned compositions that obtains is added dextrin, and fully mixing is put 60-80 ℃ of drying, pulverizes; With the abundant mixing of correctives (for example steviosin), granulate again, drying, promptly.
More than described the preferred embodiment for the present invention, so it is not in order to limit the present invention.Those skilled in the art can not depart from the improvement and the variation of category of the present invention and spirit to embodiment disclosed herein.
Claims (10)
1, a kind of Chinese medicine composition for the treatment of diabetic retinopathy, its crude drug by following weight is formed: Fructus Lycii 15-35 part, Herba Dendrobii 10-25 part, Radix Salviae Miltiorrhizae 10-25 part, Cortex Moutan 5-20 part, Radix Scrophulariae 5-20 part, Flos Chrysanthemi 5-20 part and Radix Notoginseng 5-20 part, the source of described crude drug are Chinese crude drug or the Chinese medicine extract that is equivalent to above-mentioned Chinese crude drug crude drug amount.
2, the described Chinese medicine composition of claim 1, wherein said crude drug is: Fructus Lycii 20-30 part, Herba Dendrobii 15-20 part, Radix Salviae Miltiorrhizae 15-20 part, Cortex Moutan 10-15 part, Radix Scrophulariae 10-15 part, Flos Chrysanthemi 10-15 part and Radix Notoginseng 10-15 part.
3, the described Chinese medicine composition of claim 1, wherein said crude drug is: 12.6 parts of 25.2 parts of Fructus Lycii, 16.8 parts of Herba Dendrobiis, 16.8 parts of Radix Salviae Miltiorrhizaes, 12.6 parts of Cortex Moutans, 12.6 parts of Radix Scrophulariaes, 12.6 parts of Flos Chrysanthemis and Radix Notoginseng.
4, the described Chinese medicine composition of claim 1, wherein, Fructus Lycii, Herba Dendrobii, Radix Salviae Miltiorrhizae, Radix Scrophulariae and Flos Chrysanthemi are the water extract of medical material; Radix Notoginseng and Cortex Moutan are the ethanol extraction of medical material.
5, the preparation method of each described Chinese medicine composition of claim 1-4 may further comprise the steps:
(1) Radix Notoginseng and Cortex Moutan are obtained ethanol extraction with ethanol extraction;
(2) Fructus Lycii, Herba Dendrobii, Radix Salviae Miltiorrhizae, Radix Scrophulariae and chrysanthemum with water are extracted, and use ethanol precipitation, get supernatant and obtain water extract;
(3) ethanol extraction and water extract are merged.
6, a kind of medicine of treatment of diabetic retinopathy change is made by each described Chinese medicine composition and pharmacy acceptable auxiliary among the claim 1-4.
7, the described medicine of claim 6, it is a peroral dosage form.
8, the described medicine of claim 7, it is honeyed pill, water-honeyed pill, the watered pill, granule, capsule, tablet, oral liquid or syrup.
9, the preparation method of the described medicine of claim 6, comprising:
(1) Radix Notoginseng and Cortex Moutan are obtained ethanol extraction with ethanol extraction;
(2) Fructus Lycii, Herba Dendrobii, Radix Salviae Miltiorrhizae, Radix Scrophulariae and chrysanthemum with water are extracted, and use ethanol precipitation, get supernatant and obtain water extract;
(3) ethanol extraction and water extract are merged;
(4) be concentrated into relative density 1.00-1.25 and make extractum, add the pharmacy acceptable auxiliary again, obtain described medicine.
10, the application of the described compositions of claim 1 in the medicine that the preparation treatment of diabetic retinopathy becomes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100653126A CN100446800C (en) | 2006-03-17 | 2006-03-17 | Chinese traditional medicine composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100653126A CN100446800C (en) | 2006-03-17 | 2006-03-17 | Chinese traditional medicine composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101036752A CN101036752A (en) | 2007-09-19 |
| CN100446800C true CN100446800C (en) | 2008-12-31 |
Family
ID=38888060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100653126A Expired - Fee Related CN100446800C (en) | 2006-03-17 | 2006-03-17 | Chinese traditional medicine composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100446800C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109745452A (en) * | 2017-11-01 | 2019-05-14 | 北京盈科瑞创新药物研究有限公司 | It is a kind of for treating the Chinese medicine composition and preparation method thereof of senile retinal macular degeneration |
-
2006
- 2006-03-17 CN CNB2006100653126A patent/CN100446800C/en not_active Expired - Fee Related
Non-Patent Citations (6)
| Title |
|---|
| 15年来糖尿病视网膜病变中医研究进展. 张力.北京中医，第3期. 1996 |
| 15年来糖尿病视网膜病变中医研究进展. 张力.北京中医，第3期. 1996 * |
| 中医药治疗糖尿病视网膜病变回眸研究. 王纯痒等.中西医结合心脑血管病杂志，第3卷第1期. 2005 |
| 中医药治疗糖尿病视网膜病变回眸研究. 王纯痒等.中西医结合心脑血管病杂志，第3卷第1期. 2005 * |
| 降糖明目胶囊对糖尿病视网膜新生血管抑制作用的观察. 王津津等.首都医科大学学报，第26卷第3期. 2005 |
| 降糖明目胶囊对糖尿病视网膜新生血管抑制作用的观察. 王津津等.首都医科大学学报，第26卷第3期. 2005 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101036752A (en) | 2007-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101167863B (en) | Proprietary Chinese medicine for treating diabetes and nephrosis and preparing method thereof | |
| CN101085039B (en) | Composition for preventing and treating diabetes (hyperglycaemia) and its preparation method | |
| CN101849950A (en) | Application of rotundic acid in preparing blood lipid regulating medicines | |
| CN101849987B (en) | Preparation of Chinese angelica and astragalus root mixture ethanol extract and aqueous extract and application in intervening in pulmonary fibrosis | |
| CN101336974B (en) | Blood sugar and fat reducing traditional Chinese medicine with function of comprehensively adjusting body metabolism and preparation method thereof | |
| CN109512870B (en) | Pharmaceutical composition, preparation method and application thereof | |
| CN100446800C (en) | Chinese traditional medicine composition | |
| CN101953887A (en) | Medicinal composition for preventing and treating diabetic complications and preparation method thereof | |
| CN102178236A (en) | Blood sugar reducing and cardiovascular and cerebrovascular complication preventing soft capsules and preparation method thereof | |
| CN100400081C (en) | Medicine for treating diabetes and production method thereof | |
| CN108815391A (en) | A kind of preparation process of double Herba Dendrobii extracts of liver damage protection function | |
| CN104042928B (en) | A kind of pharmaceutical composition for treating diabetes and its production and use | |
| CN102441064A (en) | Traditional Chinese medicine composition for treating diabetes and preparation thereof | |
| CN105998697A (en) | Medicine composition for treating esophagus cancer | |
| CN101804128B (en) | Medicine composition, and use thereof in preparing medicine for curing inflammatory enteropathy | |
| CN106177416B (en) | A kind of traditional Chinese medicinal composition with effect of reducing blood sugar and preparation method thereof | |
| CN104189044A (en) | Application of spanishneedles herb extract in preparation of hypoglycemic agent | |
| CN103800449B (en) | A kind of Chinese medicine composition for the treatment of Yin Xu Nei Re Zheng type 2 diabetes mellitus | |
| CN104352748A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof | |
| CN103989940A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN101961383A (en) | Medicament for oral administration for treating alcoholic fatty liver and preparation method thereof | |
| CN108553540A (en) | A kind of preparation process of tablet that treating depression | |
| CN102085227B (en) | Preparation with function of reducing blood sugar and preparation method thereof | |
| CN115025163B (en) | Double golden camellia traditional Chinese medicine composition and preparation method and application thereof | |
| CN103372055B (en) | Extraction process, the total polyphenols composition and use thereof of hypoglycemic activity composition total polyphenols in Cortex Cinnamomi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING TONG REN HOSPITAL, CAPITAL MEDICAL UNIVER Free format text: FORMER OWNER: ZHI NAN Effective date: 20071228 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20071228 Address after: Postcode of No. 1 East Lane, Beijing, Dongcheng District, China: 100730 Applicant after: BEIJING TONGREN HOSPITAL, CAPITAL MEDICAL University Address before: 4-2-1, 101 Hutong, Hutong, Dongcheng District, Beijing, Suzhou 100005, China Applicant before: Zhi Nan |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081231 |